Donald Opila, MD
Geriatric Medicine · Scottsdale, AZNPI 1780684324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Amgen at 33.6% of the total. Reporting peaked in 2019 at $548 and has fallen 50.2% since, to $273 in 2025.
Across 97 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$608
- AstraZeneca$464
- Mylan Specialty L.p.$103
- Novartis$92
- E.r. Squibb & Sons, L.L.C.$88
- Pfizer$77
- plus $377 from 13 others
What the payments were for
- Food & beverage$1,77998%
- Education$292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $608 |
| AstraZeneca | 16 | $464 |
| Mylan Specialty L.p. | 5 | $103 |
| Novartis | 4 | $92 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Pfizer | 5 | $77 |
| Boehringer Ingelheim | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| AbbVie | 2 | $45 |
| Novo Nordisk | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 3 | $28 |
| GSK | 2 | $27 |
| Verona Pharma, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $24 |
| Viatris Specialty LLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,809 in reported general payments places this provider in the 85th percentile of 75 geriatric medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 213 | $201,284 |
| JardianceEmpagliflozin | 81 | $75,472 |
| FarxigaDapagliflozin Propanediol | 89 | $72,947 |
| XareltoRivaroxaban | 63 | $62,440 |
| MyrbetriqMirabegron | 46 | $44,759 |
| OzempicSemaglutide | 26 | $44,438 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $36,246 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $35,052 |
| OxycontinOxycodone Hcl | 29 | $27,728 |
| GemtesaVibegron | 21 | $19,975 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $15,553 |
| JanuviaSitagliptin Phosphate | 19 | $13,901 |
| MounjaroTirzepatide | 12 | $11,873 |
| LinzessLinaclotide | 17 | $10,391 |
| Bydureon BciseExenatide Microspheres | 12 | $9,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin, Paxlovid | $77 | $212,881265 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $62 | $81,73394 claims |
| AstraZenecaFarxiga | $464 | $72,94789 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $27 | $71,29898 claims |
| Astellas Pharma US IncMyrbetriq | $11 | $44,75946 claims |
| Novo NordiskOzempic | $30 | $44,43826 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $19,97521 claims |
| AbbVieLinzess, Synthroid | $45 | $13,21275 claims |
| Lilly USA, LLCMounjaro | $14 | $11,87312 claims |
| NovartisEntresto | $92 | $9,40213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 75 geriatric medicine providers in Arizona.
Other geriatric medicine in Scottsdale
- Scott BernsteinScottsdale$3K
- Matthew SkinnerScottsdale$95
- Daniel FeatherstonScottsdale$57
- John MiglianoTucson$100K
- Robin MacdougallPhoenix$51K
- John HomanTucson$18K
- Raghav MohindraPrescott Valley$16K
- Albert RuttingerSurprise$11K
- Rikesh DesaiSurprise$8K
- Aureliano CifuentesTempe$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.